Glucagon-like peptide-1 (GLP-1) receptor agonists are a class of medications primarily prescribed for type 2 diabetes mellitus and, in specific formulations, for weight management
A 2025 narrative review in Clinical Therapeutics found that across 19 real-world studies, oral semaglutide delivered a median HbA1c reduction of around 1% and a median body weight reduction of 2 to 3 kg at six months, while showing a safety profile that was broadly in line with clinical trials (source)
Every product was determined to have excelled in each category by our editorial team, which is composed of in-house writers and editors as well as contributorsalong with special consideration from dermatologists
Sjekk derfor varens emballasje for oppdatert ingrediensliste, advarsler og instruksjoner.
Consoli A, Nurjhan N, Capani F, Gerich J
Reviewed by Julie Boora , Superintendent Pharmacist & Clinical Director, TribElle Health Ltd (GPhC Reg